<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Alpivab EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2E74B5;
	font-weight:normal;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Beschriftung Char\,Beschriftung Char Char\,Beschriftung Char Char Char Char\,Beschriftung Char Char1\,Beschriftung Char1\,Beschriftung Char1 Char Char\,Tab\,Tab\/Fig\,Tab\/Fig Char\,Tab\/Fig Char Char\,Tab\/Fig Char Char Char Char\,Tab\/Fig Char1 Char Char";
	mso-style-link:"Caption Char\,Beschriftung Char Char2\,Beschriftung Char Char Char\,Beschriftung Char Char Char Char Char\,Beschriftung Char Char1 Char\,Beschriftung Char1 Char\,Beschriftung Char1 Char Char Char\,Tab Char\,Tab\/Fig Char1\,Tab\/Fig Char Char1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:150%;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Text1, li.Text1, div.Text1
	{mso-style-name:"Text 1";
	mso-style-link:"Text 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
span.Text1Char
	{mso-style-name:"Text 1 Char";
	mso-style-link:"Text 1";
	font-family:"Arial",sans-serif;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Calibri Light",sans-serif;
	color:#2E74B5;}
p.BoldHdgUnnumbered, li.BoldHdgUnnumbered, div.BoldHdgUnnumbered
	{mso-style-name:"Bold Hdg Unnumbered";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Beschriftung Char Char2\,Beschriftung Char Char Char\,Beschriftung Char Char Char Char Char\,Beschriftung Char Char1 Char\,Beschriftung Char1 Char\,Beschriftung Char1 Char Char Char\,Tab Char\,Tab\/Fig Char1\,Tab\/Fig Char Char1";
	mso-style-link:"Caption\,Beschriftung Char\,Beschriftung Char Char\,Beschriftung Char Char Char Char\,Beschriftung Char Char1\,Beschriftung Char1\,Beschriftung Char1 Char Char\,Tab\,Tab\/Fig\,Tab\/Fig Char\,Tab\/Fig Char Char\,Tab\/Fig Char Char Char Char\,Tab\/Fig Char1 Char Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar1
	{mso-style-name:"C-Body Text Char1";
	mso-style-link:"C-Body Text";
	font-family:"Times New Roman",serif;}
p.ResponseText, li.ResponseText, div.ResponseText
	{mso-style-name:"Response Text";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar
	{mso-style-name:"C-Body Text Char";}
p.TableTextFootnote, li.TableTextFootnote, div.TableTextFootnote
	{mso-style-name:"TableText Footnote";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.1in;
	text-indent:-.1in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#0070C0;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img width=22
height=18 id="Bild 1" src="Alpivab%20EN%20PI%20clean_files/image002.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicinal product is subject
to additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.       NAME OF </span></b><b><span lang=EN-GB>THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab 200&nbsp;mg
concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each 20&nbsp;mL
vial of concentrate contains 200&nbsp;mg peramivir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;mL concentrate
for solution for infusion contains 10&nbsp;mg peramivir (anhydrous base).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL of
concentrate contains 0.154&nbsp;millimole (mmol) sodium, which is 3.54&nbsp;mg
of sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate for
solution for infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear,
colourless, solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab is
indicated for the treatment of uncomplicated influenza in adults and children
from the age of 2 years (see sections 4.4 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2     Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>Alpivab should be administered as a single intravenous dose within
48 hours of the onset of symptoms of influenza.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>The recommended single intravenous dose of peramivir depends on age
and body weight as shown in Table 1.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB style='color:red'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal'><a name="_Hlk506883324"><b><span lang=EN-GB>Table 1: Peramivir
dose based on age and body weight </span></b></a></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:-.25pt;border-collapse:collapse;border:none'>
 <tr style='height:.4in'>
  <td width=336 style='width:3.5in;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:.4in'>
  <p class=MsoNormal style='line-height:14.0pt'><b><span lang=EN-GB>Age and
  body weight</span></b></p>
  </td>
  <td width=268 style='width:201.3pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:.4in'>
  <p class=MsoNormal style='line-height:14.0pt'><b><span lang=EN-GB>Recommended
  single dose</span></b></p>
  </td>
 </tr>
 <tr style='height:.3in'>
  <td width=336 style='width:3.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>Children aged
  from 2 years and &lt;50 kg</span></p>
  </td>
  <td width=268 style='width:201.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>12 mg/kg</span></p>
  </td>
 </tr>
 <tr style='height:.3in'>
  <td width=336 style='width:3.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>Children aged
  from 2 years and &#8805;50 kg body weight</span></p>
  </td>
  <td width=268 style='width:201.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>600 mg</span></p>
  </td>
 </tr>
 <tr style='height:.3in'>
  <td width=336 style='width:3.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>Adults and
  adolescents (13 years and older)</span></p>
  </td>
  <td width=268 style='width:201.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.3in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>600 mg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required based on age (see sections 4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk503790927"></a><a
name="_Hlk499654234"><i><span lang=EN-GB>Renal impairment</span></i></a></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk503874094"><span
lang=EN-GB>The dose should be reduced for adults and adolescents (13 years and
older) with absolute glomerular filtration rate (GFR) below 50&nbsp;mL/min as
shown in Table 2 (see sections 4.4 and 5.2). </span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.6in;text-indent:-.6in;line-height:normal'><a name="_Ref499728619"><span
style='font-size:11.0pt'>Table</span></a><span style='font-size:11.0pt'> 2: Peramivir
dose for adults and adolescents (from 13 years and 50 kg) based on absolute GFR</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:-.25pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=288 style='width:3.0in;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><b><span
  lang=EN-GB>Absolute Glomerular Filtration Rate (GFR)*</span></b></p>
  </td>
  <td width=316 style='width:237.3pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><b><span
  lang=EN-GB>Recommended single dose</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=288 valign=top style='width:3.0in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>&#8805;50</span></p>
  </td>
  <td width=316 valign=top style='width:237.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>600 mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=288 valign=top style='width:3.0in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>30 to 49</span></p>
  </td>
  <td width=316 valign=top style='width:237.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>300 mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=288 valign=top style='width:3.0in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>10 to 29</span></p>
  </td>
  <td width=316 valign=top style='width:237.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><span
  lang=EN-GB>200 mg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>*Absolute GFR not adjusted for body surface
area</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In adults and adolescents (from 13 years and 50 kg) with chronic
renal impairment maintained on haemodialysis, peramivir should be administered
after dialysis at a dose adjusted for renal function (Table&nbsp;2).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=ResponseText align=left style='text-align:left'><span
style='font-size:11.0pt'>There are insufficient clinical data available in
children and adolescents aged less than 13 years or with body weight less than
50 kg with renal impairment to be able to make any dosing recommendation.</span></p>

<p class=ResponseText align=left style='text-align:left'>&nbsp;</p>

<p class=ResponseText align=left style='text-align:left'><i><span
style='font-size:11.0pt'>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is required in patients with hepatic impairment (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:#002060'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk500172668"><i><span
lang=EN-GB>Paediatric population</span></i></a></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of peramivir in children aged under 2 years
has not yet been established. No data are available.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB> </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab is administered
via intravenous infusion for 15 to 30&nbsp;minutes. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For instructions on dilution of the medicinal product before
administration, see section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Serious hypersensitivity</span></u><u><span
lang=EN-GB> r</span></u><u><span lang=EN-GB>eactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Anaphylactic
reactions and serious skin reactions (including erythema multiforme, toxic
epidermal necrolysis and Stevens-Johnson syndrome) have been reported with peramivir
(see section 4.8). If any hypersensitivity reaction occurs during infusion of peramivir,
the infusion must be stopped immediately and appropriate management should be
instituted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Neuropsychiatric
events</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Delirium,
hallucinations and abnormal behaviour have been reported in patients with
influenza who were receiving peramivir. These events were reported primarily
among paediatric patients and often had an abrupt onset and rapid resolution.
The contribution of peramivir to these events has not been established.
Patients with influenza should be closely monitored for signs of abnormal behaviour.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText><u><span lang=EN-GB style='color:windowtext;font-style:
normal'>Reduced renal function</span></u></p>

<p class=MsoBodyText><s><u><span lang=EN-GB style='color:red;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></s></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;font-style:normal'>Acute
renal failure, renal failure, pre-renal failure, renal disorder, anuria,
nephritis, and increased blood creatinine have been reported in patients with
influenza who were receiving peramivir. Most of the cases occurred in elderly
patients with comorbidities and multiple concomitant medicinal products. The
contribution of peramivir to these events has not been established. Patients
with influenza and already existing diseases should be closely monitored for
renal function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:14.0pt'><u><span lang=EN-GB>Limitations of the clinical data</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:14.0pt'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>The efficacy of peramivir as a single dose treatment for
uncomplicated influenza was demonstrated in a single placebo-controlled study
conducted in 300&nbsp;adult patients in Japan during the 2007/2008 influenza
season. The recommended 600 mg single intravenous dose resulted in shortening
of the median time to alleviation of symptoms by 21 hours (see section 5.1).</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Available data
do not support a conclusion that peramivir is effective in patients with
influenza B or in patients with complicated influenza.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:red'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Resistance to peramivir</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Influenza A/H1N1 viruses that contain the
H275Y mutation have reduced susceptibility to peramivir and oseltamivir. In a
clinical trial, no statistically significant clinical benefit could be
demonstrated for peramivir over placebo in patients infected with the A/H1N1
virus containing the H275Y mutation. Available information on influenza drug
susceptibility should be taken into account when deciding whether to use peramivir
(see section 5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:red'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Risk of bacterial
infections</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence for efficacy of peramivir in any illness caused by agents other than
influenza viruses. Serious bacterial infections may begin with influenza-like
symptoms or may coexist with or occur as complications during the course of
influenza. Peramivir has not been shown to prevent such complications. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains 212.4&nbsp;mg sodium per 3 vials,
equivalent to 10.6% of the World Health Organization (WHO) recommended maximum
daily intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The potential
for interactions of peramivir with other medicines is low, based on the known
elimination pathway of peramivir. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Live attenuated influenza vaccines are not
recommended to be used until 48&nbsp;hours following Alpivab administration<span
style='color:red'> </span>due to a theoretical risk that peramivir could reduce
the immunogenicity of the vaccine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6     </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no or
limited amount of data (less than 300 pregnancies outcomes) from the use of
peramivir in pregnant women. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal studies
do not indicate direct or indirect harmful effects with respect to reproductive
toxicity (see section 5.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As a
precautionary measure, it is preferable to avoid the use of peramivir during
pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk506829124"><u><span
lang=EN-GB>Breast-feeding</span></u></a></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>Available
pharmacodynamic/toxicological data in animals have shown excretion of peramivir
in milk (see section 5.3).</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>A risk
to the newborns/infants cannot be excluded.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A decision must
be made whether to discontinue breast-feeding or to discontinue/abstain from peramivir
therapy taking into account the benefit of breast-feeding for the child and the
benefit of therapy for the woman.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No human data on
the effect of peramivir on fertility are available. Peramivir had no effects on
mating or fertility in animal studies (see section 5.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7     Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peramivir has no
or negligible influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>The most important
serious adverse reactions associated with permivir in patients are anaphylaxis
and </span><span lang=EN-GB>skin reactions, including erythema multiforme and
Stevens-Johnson Syndrome. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Among 467&nbsp;adult
subjects with uncomplicated influenza who received a single intravenous dose of
</span><span lang=EN-GB>peramivir</span><span lang=EN-GB> 600&nbsp;mg in
clinical trials, the most commonly observed adverse reactions were neutrophil
count decreased (3.2&nbsp;%) and nausea (2.4&nbsp;%). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB>Tabulated list of
adverse reactions</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Frequencies are
defined as very common (&#8805;1/10), common (&#8805;1/100 to &lt;1/10),
uncommon (&#8805;1/1000 to &lt;1/100), rare (&#8805;1/10,000 to &lt;1/1000),
very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="_Hlk498529576"><b><span
lang=EN-GB>Table 3: <span style='color:black;background:white'>Adverse
reactions in studies investigating peramivir for treatment of uncomplicated
influenza in adults </span></span></b></a></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=648
 style='margin-left:-.5pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:28.5pt'>
   <td width=144 rowspan=2 style='width:1.5in;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.5pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>System
   Organ Class (SOC)</span></b></p>
   </td>
   <td width=504 colspan=4 style='width:5.25in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>Adverse Reaction According to Frequency*</span></b></p>
   </td>
  </tr>
  <tr style='height:15.75pt'>
   <td width=120 style='width:1.25in;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Common</span></b></p>
   </td>
   <td width=180 style='width:135.0pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Uncommon</span></b></p>
   </td>
   <td width=84 style='width:63.0pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rare</span></b></p>
   </td>
   <td width=120 style='width:1.25in;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Unknown</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:29.25pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:29.25pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Blood and
  lymphatic system disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>neutrophil
  count decreased</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:29.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:30.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Immune
  system disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>anaphylactic
  reaction*, anaphylactic shock*</span></p>
  </td>
 </tr>
 <tr style='height:137.2pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:137.2pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Metabolism
  and nutrition disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:137.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>blood lactate
  dehydrogenase increased</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:137.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>decreased
  appetite, blood albumin decreased, blood chloride increased, blood glucose
  decreased, blood lactate dehydrogenase decreased, blood potassium increased,
  blood sodium increased, blood uric acid increased, protein total increased</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:137.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:137.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:30.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Psychiatric
  disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insomnia</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>abnormal
  behaviour*, delirium*</span></p>
  </td>
 </tr>
 <tr style='height:30.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nervous
  system disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>hypoaesthesia,
  paraesthesia</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Eye
  disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>vision blurred</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:30.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cardiac
  disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>electrocardiogram
  QT prolonged</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:40.0pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Gastrointestinal
  disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>nausea,
  vomiting</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>abdominal pain
  upper, abdominal discomfort, gastritis</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:75.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hepatobiliary
  disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>increased
  gamma-glutamyltransferase</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>liver
  disorder*, alanine aminotransferase increased*, aspartate aminotransferase
  increased* </span></p>
  </td>
 </tr>
 <tr style='height:45.75pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:45.75pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:45.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:45.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>dermatitis,
  drug eruption, eczema, urticaria</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:45.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>erythema
  multiforme</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:45.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>dermatitis
  exfoliative*, Stevens-Johnson syndrome*</span></p>
  </td>
 </tr>
 <tr style='height:43.5pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>arthralgia,
  blood creatine phosphokinase increased</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:63.8pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:63.8pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Renal and
  urinary disorders</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:63.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:63.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>blood urea
  increased, blood present in urine, urobilin present in urine, blood
  creatinine increased, urine ketone body increased</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:63.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:63.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>acute kidney
  injury*, renal impairment*</span></p>
  </td>
 </tr>
 <tr style='height:43.5pt'>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>General
  disorders and administration site conditions</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=180 style='width:135.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>chest
  discomfort, fatigue</span></p>
  </td>
  <td width=84 style='width:63.0pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=TableTextFootnote><span style='color:windowtext'>*These events
reported from post-authorization use occurred with different dosage and dosing
schedule to that described in the SmPC.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Paediatrics</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In
paediatric subjects (age 2 to 17&nbsp;years) with uncomplicated influenza enrolled
in a clinical trial, the safety profile of peramivir was similar to that
reported in adults. Common a</span><span lang=EN-GB>dverse reactions not
reported in adults were injection site rash, pyrexia, tympanic membrane
hyperaemia, psychomotor hyperactivity, and pruritus. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via the national reporting
system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>There is no experience of acute overdose with peramivir
in humans. Treatment of an overdose should consist of general supportive
measures including monitoring of vital signs and observation of the clinical
status of the patient. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Peramivir is cleared by renal excretion and can be cleared by haemodialysis.
There is no specific antidote to treat an overdose of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: Antivirals for systemic use,
neuraminidase inhibitors ATC code</span><b><span lang=EN-GB>: </span></b><span
lang=EN-GB> </span><span lang=EN-GB>J05AH03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Peramivir is an inhibitor of influenza virus neuraminidase, an
enzyme that releases viral particles from the plasma membrane of infected cells
and is also important for viral entry into uninfected cells, which causes further
spread of infectious virus in the body.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>In-vitro</span></u></i><u><span
lang=EN-GB> activity </span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Neuraminidase
inhibition occurred at very low peramivir concentrations <i>in-vitro</i>, with
median inhibitory concentration 50% (IC<sub>50</sub>) values of 0.13 nanomolar
(nM) to 0.99 nM against influenza A and B strains.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk503779250"><i><span lang=EN-GB>Resistance</span></i></a></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In a clinical
trial in which 245 subjects <a name="_Hlk500240383">were infected at baseline
with influenza</a> A/H1N1 containing the H275Y mutation, the median baseline IC<sub>50</sub>
values for peramivir, oseltamivir and zanamivir were 51.0 nM, 487.6 nM and 0.95
nM, respectively. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In clinical
trials, H275Y was the only resistance-associated treatment-emergent mutation in
the neuraminidase gene that occurred in virus obtained from more than one
peramivir-treated subject (in 9 of 481[1.9 %] infected with the A/H1N1
influenza virus). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Cross resistance</span></i></p>

<p class=BodytextAgency style='margin-bottom:0in;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>The H275Y substitution is associated with
reduced susceptibility to peramivir and oseltamivir. Cross-resistance between
peramivir and each of oseltamivir and zanamivir may also occur. </span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB
style='color:red'><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Clinical
studies</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><a name="_Hlk498508026"><i><span
lang=EN-GB>Uncomplicated influenza in adults</span></i></a></p>

<p class=MsoNormal><span lang=EN-GB>A randomised, multicentre, double-blind
trial conducted in Japan evaluated a single intravenous administration of
peramivir&nbsp;300&nbsp;mg or&nbsp;600 mg, or placebo administered over
30&nbsp;minutes in subjects 20 to 64&nbsp;years of age with<span
style='color:red'> </span>uncomplicated influenza. Subjects were eligible if
they had fever greater than 38&nbsp;<a name="_Hlk503778028">°C</a> and a
positive rapid antigen test for influenza virus, accompanied by at least two of
the following symptoms: cough, nasal symptoms, sore throat, myalgia,
chills/sweats, malaise, fatigue or headache. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Study treatment was started within
48&nbsp;hours of onset of symptoms. Subjects participating in the trial were
required to self-assess their influenza symptoms as none, mild, moderate
or severe twice daily. The primary endpoint, time to alleviation of symptoms,
was defined as the number of hours from initiation of study drug until the
start of the 24&nbsp;hour period in which all seven symptoms of influenza
(cough, sore throat, nasal congestion, headache, feverishness, myalgia and
fatigue) were either absent or present at a level no greater than mild for at
least 21.5&nbsp;hours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The intent to treat influenza population
(ITTI) included 296 subjects with influenza confirmed by polymerase chain
reaction (PCR). Among the 97&nbsp;subjects enrolled in the peramivir
600&nbsp;mg dose group, 99&nbsp;% were infected with influenza A virus (subtypes
H1 and H3; 71&nbsp;% and 26&nbsp;%, respectively) and 1&nbsp;% with influenza B
virus. At enrollment 85&nbsp;% of the 296 subjects had a composite influenza
symptom score &lt;15. The mean temperature at enrolment was 38.6&nbsp;°C
(axillary). Key efficacy results are presented in Table 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Table 4: Key
efficacy results from study 0722T0621 (ITTI Population)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=557
 style='width:418.1pt;border-collapse:collapse'>
 <tr>
  <td width="45%" valign=top style='width:45.68%;border:inset 1.0pt;border-bottom:
  solid windowtext 1.0pt;padding:1.2pt 1.2pt 1.2pt 1.2pt'></td>
  <td width="27%" valign=top style='width:27.14%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  style='color:black'>Peramivir 600 mg</span></b><span style='color:black'> </span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>n=97</span></p>
  </td>
  <td width="27%" valign=top style='width:27.2%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  style='color:black'>Placebo</span></b><span style='color:black'> </span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>n=100</span></p>
  </td>
 </tr>
 <tr>
  <td width="45%" valign=top style='width:45.68%;border:inset 1.0pt;border-top:
  none;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal style='line-height:normal'>Time to alleviation of symptoms</p>
  <p class=MsoNormal style='line-height:normal'><span style='color:black'>median
  (hours)</span></p>
  <p class=MsoNormal style='line-height:normal'><span style='color:black'>(95&nbsp;%
  CI)</span></p>
  </td>
  <td width="27%" valign=bottom style='width:27.14%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>59.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>(54.4, 68.1)</span></p>
  </td>
  <td width="27%" valign=bottom style='width:27.2%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>81.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>(68.0, 101.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width="45%" valign=top style='width:45.68%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black'>Time
  to recovery of normal temperature median (hours)</span></p>
  <p class=MsoNormal style='line-height:normal'><span style='color:black'>(95&nbsp;%
  CI)</span></p>
  </td>
  <td width="27%" valign=bottom style='width:27.14%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>30.2</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>(25.9, 31.9)</span></p>
  </td>
  <td width="27%" valign=bottom style='width:27.2%;padding:1.2pt 1.2pt 1.2pt 1.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>42.4</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  style='color:black'>(32.9, 46.5)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>CI = Confidence
Interval </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Uncomplicated
influenza in paediatric subjects aged 2-17 years</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of peramivir
was evaluated in a randomised, active-controlled study of 110&nbsp;subjects
with uncomplicated influenza who received open label treatment with a single
dose of peramivir (600&nbsp;mg for subjects 13 to 17&nbsp;years of age and 12&nbsp;mg/kg
up to a maximum dose of 600&nbsp;mg in subjects 2 to 12&nbsp;years of age) or oral
oseltamivir administered twice daily for 5 days. </span><span lang=EN-GB>The
ITTI population included 84 subjects with influenza confirmed by PCR. Among the
93 subjects enrolled in the peramivir dose group, 43% were infected with
influenza A virus (subtypes H1 and H3; 54 % and 46 %, respectively) and 27%
with influenza B virus. </span><span lang=EN-GB>Randomisation was 4:1 for peramivir
and oseltamivir. Treatment was given or commenced within 48&nbsp;hours of onset
of symptoms of influenza. Efficacy (time to resolution of fever; time to
resolution of influenza symptoms, viral shedding, virus susceptibility) was a
secondary endpoint.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Subjects
receiving peramivir experienced a median time to alleviation of their combined
influenza symptoms of 79.0 hours and the median time to recovery to normal
temperature (less than 37&nbsp;°C) was approximately 40.0&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly
patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical trials
in which single intravenous doses of peramivir were administered to patients
with uncomplicated influenza included few subjects aged 65 and over (n=10).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has deferred
the obligation to submit the results of studies with Alpivab in one or more
subsets of the paediatric population for the treatment of influenza (see
section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic parameters following intravenous (IV) administration of peramivir
(0.17 to 2&nbsp;times the recommended dose) showed a linear relationship
between dose and exposure parameters (maximum serum concentration [C<sub>max</sub>]
and area under the curve [AUC]). Following intravenous administration of a
single dose of peramivir 600&nbsp;mg over 30&nbsp;minutes, C<sub>max</sub> was
reached at the end of infusion. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In-vitro</span></i><span
lang=EN-GB> binding of peramivir to human plasma proteins is less than 30&nbsp;%.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on a
population pharmacokinetic analysis, the central volume of distribution was
12.56&nbsp;L.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peramivir is not
significantly metabolised in humans.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The elimination half-life of peramivir following IV administration
to healthy subjects of 600&nbsp;mg as a single dose is approximately 20&nbsp;hours.
The major route of elimination of peramivir is via the kidney. Renal clearance
of unchanged peramivir accounts for approximately 90&nbsp;% of total clearance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Race</span></i></p>

<p class=MsoNormal><a name="_Hlk498601677"><span lang=EN-GB>In simulations of a
single dose of 600 mg, the predicted AUC in Asians (AUC<sub>0-24</sub> 88,800
ng</span></a><span lang=EN-GB></span><span lang=EN-GB>h/mL) was slightly
higher as compared to Non-Asians (AUC<sub>0-24</sub> 77,200 ng</span><span
lang=EN-GB></span><span lang=EN-GB>h/mL).&nbsp; </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Gender</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of peramivir following a 600 mg intramuscular (IM) injection was
similar in males and females with AUC<sub>0-&#8734;</sub> of 76,600&nbsp;nghr/mL
and 101,000&nbsp;nghr/mL, respectively, and C<sub>max</sub> of 27,760&nbsp;ng/mL
and 34,710&nbsp;ng/mL, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk503609111"><i><span
lang=EN-GB>Paediatrics</span></i></a></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk497130888"><span
lang=EN-GB>The pharmacokinetics of peramivir has been evaluated in a study in
paediatric subjects 2 to 17&nbsp;years of age with uncomplicated influenza.
Pharmacokinetic sampling in this study was limited to approximately 3&nbsp;hours
after administration of peramivir. Pharmacokinetics of peramivir in subjects 2
to 17&nbsp;years of age (administered 12 mg/kg or 600 mg according to age and
body weight) and in healthy adults (administered 600&nbsp;mg) was similar
(Table 5). </span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Table 5: Pharmacokinetic
parameters in paediatric subjects </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:28.3pt'>
  <td width=138 style='width:103.25pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt;height:28.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt'>Age Group</span></b></p>
  </td>
  <td width=138 style='width:103.5pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:28.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=48 style='width:.5in;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:28.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt'>N</span></b></p>
  </td>
  <td width=120 style='width:1.25in;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:28.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt'>C<sub>max</sub> (ng/mL)</span></b></p>
  </td>
  <td width=144 style='width:1.5in;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:28.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt'>AUC<sub>last</sub> (ng</span></b><b><span
  style='font-size:11.0pt'>h/mL)</span></b></p>
  </td>
 </tr>
 <tr style='height:17.5pt'>
  <td width=138 rowspan=3 style='width:103.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>2 years - &lt;7 years</span></b></p>
  </td>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Mean (SD)</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>28</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>53,600 (26,200)</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>74,000 (30,000)</span></p>
  </td>
 </tr>
 <tr style='height:19.3pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Geometric Mean</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:19.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>47,400</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:19.3pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>68,100</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>%CV</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>48.9</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.35pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>40.6</span></p>
  </td>
 </tr>
 <tr style='height:16.15pt'>
  <td width=138 rowspan=3 style='width:103.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>7 years - &lt;13 years</span></b></p>
  </td>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Mean (SD)</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:16.15pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>39</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>66,800 (35,400)</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:16.15pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>87,000 (40,800)</span></p>
  </td>
 </tr>
 <tr style='height:18.4pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Geometric Mean</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:18.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>61200</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:18.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>81,000</span></p>
  </td>
 </tr>
 <tr style='height:15.25pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.25pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>%CV</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.25pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.25pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>53.0</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:15.25pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>46.8</span></p>
  </td>
 </tr>
 <tr style='height:27.4pt'>
  <td width=138 rowspan=3 style='width:103.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>13 years - &lt;18</span></b></p>
  </td>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Mean (SD)</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:27.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>20</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>54,300 (17,900)</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:27.4pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>72,400 (20,000)</span></p>
  </td>
 </tr>
 <tr style='height:17.5pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Geometric Mean</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>51,500</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.5pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>69,500</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>%CV</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>33.0</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>27.6</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=138 rowspan=3 style='width:103.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><b><span style='font-size:11.0pt'>2 years - &lt;18 years</span></b></p>
  </td>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Mean (SD)</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>87</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>59,700 (29,700)</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>79,500 (34,000)</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>Geometric Mean</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>54,200</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>74,000</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=138 style='width:103.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>%CV</span></p>
  </td>
  <td width=48 style='width:.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=120 style='width:1.25in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>49.8</span></p>
  </td>
  <td width=144 style='width:1.5in;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:17.05pt'>
  <p class=C-BodyText align=center style='margin:0in;text-align:center;
  line-height:normal'><span style='font-size:11.0pt'>42.7</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SD = Standard
Deviation; CV = Coefficient of Variation</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB
style='color:red'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pharmacokinetics
of peramivir was evaluated in 20&nbsp;elderly subjects (&gt;65 years of age)
following a single 4&nbsp;mg/kg IV dose of peramivir. The elderly subjects
enrolled were aged 65 to 79 years, with a mean age of 70.1 years, with creatinine
clearance (Cockcroft-Gault calculation) CrCl<sub>cg</sub> ranging from 82.8
mL/min to 197.9 mL/min. The </span><span lang=EN-GB>pharmacokinetics in elderly
subjects was similar to non-elderly subjects.</span><span lang=EN-GB> Mean peak
concentrations of peramivir were approximately 10&nbsp;% higher in elderly
subjects following administration of a single dose when compared to young
adults (22,647 vs. 20,490&nbsp;ng/mL, respectively). Exposure (AUC<sub>0-12</sub>)
to peramivir following a single dose was approximately 33&nbsp;% higher in
elderly subjects compared to young adults (61,334 vs. 46,200&nbsp;ng</span><span
lang=EN-GB></span><span lang=EN-GB>hr/mL, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study in
subjects with various degrees of renal impairment and subjects with normal
renal function, a single 2&nbsp;mg/kg IV dose of peramivir was administered.
Serum creatinine measurements were used to calculate creatinine clearance
(Cockcroft-Gault equation). The mean AUC<sub>0-</sub></span><sub><span
lang=EN-GB style='font-family:Symbol'>µ</span></sub><span lang=EN-GB> was
increased by 28 %, 302 % and 412 % in subjects with creatinine clearance of 50&#8209;79,
30&#8209;49 and 10&#8209;29 mL/min, respectively. Haemodialysis initiated at 2&nbsp;hours
after dosing reduced systemic exposure of peramivir by 73 to 81&nbsp;%.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of peramivir in subjects with hepatic impairment has not been
studied. No clinically relevant alterations to peramivir pharmacokinetics are
expected in patients with hepatic impairment based on the route of peramivir
elimination.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3     Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Peramivir was not teratogenic in embryo-fetal
development studies in rats and rabbits and had no effects on mating or
fertility in rats up to 600&nbsp;mg/kg/day, at which exposures were
approximately 8&#8209;fold of those in humans at the clinically recommended
dose. However, in an embryo-foetal development study in rats, in which dams
received continuous infusions of peramivir from day 6&#8209;17 of gestation at
does of 50, 400 or 1000&nbsp;mg/kg/day, dose related increases in the
incidences of reduction of the renal papillae and dilatation of the ureters
were observed. The teratological importance of these findings is unclear.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carcinogenicity studies by intravenous injection of peramivir were
not performed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Peramivir was
not mutagenic or clastogenic in a battery of <i>in-vitro</i> and <i>in-vivo</i>
assays.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Acute renal
necrosis was found in rabbits at doses &#8805; 200&nbsp;mg/kg with a clear no
observed adverse effect level (NOAEL) established in multiple studies at 100&nbsp;mg/kg/day.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Two-week oral
toxicity studies were conducted in juvenile rats and rabbits, and a four-week
IV toxicity study was conducted in juvenile rats. In general, nephrotoxicity
was observed in rabbits, no unexpected toxicity was observed, and no other
target organ toxicity was identified in juvenile animals.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium hydroxide
(for pH adjustment)</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal'><span lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product must not be mixed with other medicinal products except those mentioned
in section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>After
dilution</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Chemical and physical in-use stability has
been demonstrated for 72 hours at 5 ºC and 25 ºC.</span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, the
product, once diluted, should be used immediately.</span><span lang=EN-GB> </span><span
lang=EN-GB>If not used immediately in-use storage times and conditions prior to
use are the responsibility of the user and would normally not be longer than 24
hours at 2 ºC to 8 ºC, unless dilution has taken place in controlled and
validated aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not refrigerate
or freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after dilution of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Clear glass vial (Type I) with a coated bromobutyl-rubber stopper, aluminium
overseal and flip-off cap. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of 3
single-use vials.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aseptic technique should be used during the preparation of Alpivab
to prevent inadvertent microbial contamination. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
steps should be followed to prepare a diluted solution of peramivir:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Check
the seal of each vial. Do not use if seal opening is broken or missing.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Visually
inspect the peramivir concentrate 10&nbsp;mg/mL. It must be colourless and
without particulate matter. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If a
patient receives 600&nbsp;mg peramivir the required volume of peramivir
concentrate is 60&nbsp;mL (3&nbsp;vials with 20&nbsp;mL each). In the case of a
300&nbsp;mg peramivir dose, 30&nbsp;mL (1½&nbsp;vials) of peramivir concentrate
is needed and for a 200&nbsp;mg dose, only 20&nbsp;mL (1&nbsp;vial). Fractions
of a vial may be needed for appropriate dose adjustments in children with a
bodyweight of less than 50 kg.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Add
the measured volume of peramivir concentrate into the infusion container.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Dilute
the required dose of peramivir concentrate in sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%)
or 4.5&nbsp;mg/mL (0.45&nbsp;%) solution for infusion, 5&nbsp;% dextrose or
Ringer lactate solution to a volume of 100&nbsp;mL.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Administer
the diluted solution via intravenous infusion for 15 to 30&nbsp;minutes.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Once
a diluted peramivir solution has been prepared, administer immediately or store
in a refrigerator (2&nbsp;°C to 8&nbsp;°C) for up to 24&nbsp;hours. If
refrigerated, allow the diluted peramivir solution to reach room temperature,
then administer immediately.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Discard
any unused diluted solution of peramivir after 24&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioCryst UK Ltd,
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>c/o Morgan Lewis
&amp; Bockius</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Condor House, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5-10 St. Paul's
Churchyard, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>London EC4M 8AL </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 (</span>0)
20 3289 9824</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fax: +44 (</span><span
style='color:#222222'>0) 20 3725 7789</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>E</span><span
lang=EN-GB>-mail: safety@biocryst.com</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk506824658"><b><span lang=EN-GB>8.       MARKETING
AUTHORISATION NUMBER(S) </span></b></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/18/1269/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <span style='color:blue'>http://www.ema.europa.eu</span>.<br
clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A.        MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>B.        CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>C.        OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>D.        <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:7.0pt;
margin-left:6.35pt;line-height:14.0pt;text-autospace:none'><u><span lang=EN-GB
style='color:black'>Name and address of the manufacturer(s) responsible for
batch release</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB
style='color:black'>Seqirus Vaccines Ltd<br>
Gaskill Road<br>
Speke<br>
Liverpool<br>
L24 9GR<br>
UNITED KINGDOM</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK2"><b><span lang=EN-GB>B.</span></b></a><b><span
lang=EN-GB>      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:14.0pt;text-autospace:
none'><span lang=EN-GB style='color:black'>Medicinal product subject to medical
prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of periodic safety update reports
for this medicinal product are set out in the list of Union reference dates
(EURD list) </span><span lang=EN-GB>provided for under Article 107c(7) of
Directive 2001/83/EC and any subsequent updates published on the European
medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder shall submit the first periodic safety update report for
this product within 6&nbsp;months following authorisation. </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The MAH shall perform the required pharmacovigilance activities and
interventions detailed in the agreed RMP presented in Module 1.8.2 of the
Marketing Authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab
200&nbsp;mg concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>peramivir</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;mL
concentrate contains 10&nbsp;mg peramivir (anhydrous basis).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each 20&nbsp;mL
vial contains 200&nbsp;mg peramivir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium hydroxide
(for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochloric
acid (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;vials</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use
after dilution</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>--</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioCryst UK Ltd,
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5-10 St. Paul's
Churchyard, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>London, EC4M 8AL
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UK<i> </i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/18/1269/001
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier included</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN: </span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON
THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab
200&nbsp;mg concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>peramivir</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;mL
concentrate contains 10&nbsp;mg peramivir (anhydrous base).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each 20&nbsp;mL
vial contains 200</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg
peramivir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium hydroxide
(for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochloric
acid (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use
after dilution</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>--</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioCryst UK Ltd,
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5-10 St. Paul's
Churchyard, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>London, EC4M 8AL
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UK<i> </i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/18/1269/001
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>--</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>--</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Alpivab 200 mg concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>peramivir</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=22 height=18 id="Picture 1"
src="Alpivab%20EN%20PI%20clean_files/image003.png" alt="BT_1000x858px"></span><span
lang=EN-GB>This medicine is subject to additional monitoring. This will allow
quick identification of new safety information. You can help by reporting any
side effects you may get. See the end of section 4 for how to report side
effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist.</span><span lang=EN-GB style='color:red'> </span><span
lang=EN-GB>This includes any possible side effects not listed in this leaflet.
See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What is in
this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.       What Alpivab is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.       What you need to know before you are given Alpivab </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.       How Alpivab is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.       Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.       How to store Alpivab </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.       What Alpivab is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Alpivab contains the active substance peramivir which belongs to a
group of medicines called neuraminidase inhibitors. These medicines prevent the
influenza virus from spreading inside the body. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Alpivab is used to treat adults and children aged from 2&nbsp;years
with influenza that is not severe enough to require hospitalisation. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       What you need to know before you are given
Alpivab</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>You must not receive Alpivab</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to peramivir or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor or pharmacist before you are given Alpivab if you have reduced kidney
function. Your doctor may have to adjust your dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor immediately if you experience serious skin or
allergic reactions after Alpivab is given. Symptoms may include skin or throat
swelling, difficulty breathing, blistering rash or peeling skin. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor immediately if you experience abnormal behaviour
after Alpivab is given. Symptoms may include confusion, difficulty thinking or
hallucinations. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Alpivab is not recommended in children aged under 2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Alpivab</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor or pharmacist if you are using, have recently used
or might use any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Live attenuated influenza vaccines should not be given until
48&nbsp;hours after treatment with Alpivab. This is because Alpivab may prevent
these vaccines from working well enough.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are pregnant or breast-feeding. Your doctor will advise on whether you
can be given Alpivab during pregnancy, or whether you are to stop
breast-feeding for a short period after getting Alpivab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Alpivab is not likely to change your ability to drive and use
machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Alpivab contains sodium</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>This medicine
contains <span lang=EN-GB>212.4&nbsp;</span>mg sodium (main component of
cooking/table salt) in each dose consisting of 3 vials. This is equivalent to
10.6 % of the recommended maximum daily dietary intake of sodium for an adult.<s>
</s></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><a
name="_Hlk506897833"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk506885258"><b><span lang=EN-GB>3.       How Alpivab is
given</span></b></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Alpivab is given by a healthcare profesional as a single dose within
2 days of the start of influenza symptoms. It is first diluted and then given into
a vein  by infusion (drip), over 15 to 30 minutes.  </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:-.1pt;
margin-bottom:8.0pt;margin-left:.25in;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Adults
and adolescents (13 years and older) receive 600 mg (3 Alpivab vials).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:8.0pt;margin-left:.25in;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Children
aged from 2 years weighing 50 kg or more receive 600 mg (3 Alpivab vials).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:8.0pt;margin-left:.25in;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Children
aged from 2 years weighing less than 50 kg receive 12 mg per kg body weight.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Patients
with reduced kidney function may require a reduced dose.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
6.0pt;margin-left:0in;line-height:normal'><b><span lang=EN-GB>Contact your
doctor immediately</span></b><span lang=EN-GB> if any of the following side
effects occur:</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Rare,</span></b><span lang=EN-GB> may affect up to 1 in
1,000&nbsp;people</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:.25in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>severe
skin rash with or without blisters and fever</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Not known, </span></b><span lang=EN-GB>frequency cannot be estimated
from the available data<b> </b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>very severe skin reactions, including
Steven-Johnson syndrome and dermatitis exfoliative </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>These
skin reactions are life-threatening rashes with fever and blisters and can
effect the lining of the mouth and genitals.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe</span> allergic reactions, including severe
allergic shock reaction with features such as itchy rash, swelling of the
throat and tongue, breathing difficulty, lightheadedness and vomiting</p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
6.0pt;margin-left:0in;line-height:normal'><span lang=EN-GB>Other side effects
occur with the following frequencies:</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Common</span></b><span lang=EN-GB>, may affect up to 1 in
10&nbsp;people</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low levels of a white blood cell type called
neutrophils</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood tests showing increased levels of lactate
dehydrogenase</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea (feeling sick), vomiting</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB>, may affect up to 1 in
100&nbsp;people</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased appetite</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood tests showing decreased levels of albumin,
glucose, lactate dehydrogenase</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood tests showing increased levels of
chloride, potassium, sodium, uric acid, protein total,
gamma-glutamyltransferase, creatine phosphokinase, urea, creatinine</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeplessness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced sense of touch or sensation</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal sensation such as prickling, tingling
and itchiness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blurred vision</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>prolonged time of the heart ventricle activity,
measured in the ECG</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper abdominal pain, abdominal discomfort</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of stomach lining</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin inflammation, eczema, rash, nettle-rash</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urobilin presented in the urine</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of urine ketone body</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest discomfort, fatigue</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><s><span
lang=EN-GB style='color:#0070C0'><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Not known</span></b><span lang=EN-GB>, frequency cannot be estimated
from the available data</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal behaviour, delirium</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blood test showing increased levels of alanine
aminotransferase, aspartate aminotransferase</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>acute kidney injury, reduced kidney function</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Children and Adolescents from 2 years</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Side effects were similar to adults but also included the following:</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Common</span></b><span lang=EN-GB>, may affect up to 1 in
10&nbsp;people</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>rash on the injection site</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>fever</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>red ear drum</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>restlessness</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>itching</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><s><span
lang=EN-GB style='color:#0070C0'><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:red'> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       How to store Alpivab</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the label and carton after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once diluted,
administer the prepared Alpivab solution immediately; otherwise, store </span><span
lang=EN-GB>in a refrigerator (2&nbsp;°C  8&nbsp;°C) for up to 24&nbsp;hours. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       Contents of the
pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Alpivab contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is peramivir.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Each
20&nbsp;mL vial contains </span><span lang=EN-GB>200&nbsp;mg</span><span
lang=EN-GB> peramivir. 1&nbsp;mL concentrate for solution for infusion contains
10&nbsp;mg peramivir (anhydrous base).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are sodium chloride, water
for injections, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH
adjustment).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Alpivab looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Alpivab is a
clear, colourless, sterile concentrate for solution for infusion. It is
provided in a clear glass vial with a coated rubber stopper, aluminium overseal
and flip-off cap. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each carton contains
3&nbsp;vials.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioCryst UK Ltd,
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>c/o Morgan Lewis
&amp; Bockius Condor House, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5-10 St. Paul's
Churchyard, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>London EC4M 8AL</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UK</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 (0) 20
3289 9824</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fax: +44 (0) 20
3725 7789</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>E</span><span
lang=EN-GB>-mail: safety@biocryst.com</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>Seqirus Vaccines
Limited</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>Gaskill Road,
Speke</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>Liverpool</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>L24 9GR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>UK</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was </span></b><b><span lang=EN-GB>last revised in </span></b><span
lang=EN-GB>{<b>MM/YYYY</b>}</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Use aseptic technique during the preparation of Alpivab to prevent
microbial contamination. There is no preservative or antibacterial agent in the
solution. Do not mix or co-infuse Alpivab with other medicines administered
into a vein.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Follow the steps
below in the provided order to prepare a diluted solution of Alpivab:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Check the seal of each
vial. Do not use if the seal opening is broken or missing.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Inspect the Alpivab
concentrate. It must be colourless and without particulate matter. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If a patient receives
600&nbsp;mg peramivir the required volume of Alpivab concentrate is 60&nbsp;mL
(3&nbsp;vials of 20&nbsp;mL each). In the case of a 300&nbsp;mg peramivir dose,
30&nbsp;mL (1½&nbsp;vials) of Alpivab concentrate is needed and for a
200&nbsp;mg dose, only 20&nbsp;mL (1&nbsp;vial). Fractions of a vial may be
needed for appropriate dose adjustments in children with a bodyweight of less
than 50 kg.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Add the measured volume
of Alpivab concentrate into the infusion container.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Dilute the required dose
of Alpivab concentrate in sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%) or
4.5&nbsp;mg/mL (0.45&nbsp;%) solution for infusion, 5&nbsp;% dextrose or Ringer
lactate solution to a volume of 100&nbsp;mL.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Administer the diluted
solution via intravenous infusion over 15 to 30&nbsp;minutes.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Once a diluted Alpivab
solution has been prepared, administer immediately or store in a refrigerator
(2&nbsp;°C to 8&nbsp;°C) for up to 24&nbsp;hours. If refrigerated, allow the
diluted Alpivab solution to reach room temperature, then administer
immediately.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.25in;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Discard any unused
diluted solution of Alpivab after 24&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No special
requirements for disposal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Any unused medicinal product or waste material should be
disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
